author-photo

Caroline Emery

Novartis

24

Papers

3550

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor

2018 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

2017 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (170)
BRAF-inhibitor associated MEK Mutations Increase RAF-dependent and-independent Enzymatic Activity

2017 Molecular Cancer Research
Show All
- Source
- Cite
- Save
Citations (8)
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

2016 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

2016 Oncotarget
Show All
- Source
- Cite
- Save
Citations (34)
Abstract 3027: Dual inhibition of PKC and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Landscape of genetic alterations in patients with metastatic uveal melanoma.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations

2014 Oncogene
Show All
- Source
- Cite
- Save
Citations (129)
C-RAF mutations confer resistance to RAF inhibitors

2013 Cancer Research
Show All
- Source
- Cite
- Save
Citations (25)
Abstract 3933: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

2011 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)